September 18, 2024 – The number of lives lost around the world due to infections that are resistant to the medications intended to treat them could increase nearly 70% by 2050, a new study just published in the journal The Lancet estimates.

Cumulatively, from 2025 to 2050, the world could see more than 39 million deaths that are directly attributable to antimicrobial resistance or AMR. It is important that interventions combine infection prevention, vaccination, minimisation of inappropriate antibiotic use in farming and humans, and research into new antibiotics to mitigate the number of AMR deaths that are forecasted for 2050.

TenNor is developing multiple new antimicrobial drugs with a novel mechanism of action to address the AMR challenges.

TNP-2198 is a synergistic multitargeting drug candidate currently under phase 3 clinical development for the treatment of Helicobacter pylori infections. TNP-2198 is the first new drug in 30 years specifically developed for H. pylori. TNP-2198 can overcome multidrug resistance to antibiotics currently used for the treatment of H. pylori infections.

TNP-2092 is a novel triple acting antibacterial agent with an excellent activity against multidrug resistant Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and quinolone-resistant S. aureus (QRSA). TNP-2092 possesses an extremely low frequency for the development of resistance. TNP-2092 is currently under phase 3 clinical development for the treatment of prosthetic joint infections.

Link to Lancet article:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01076-6/fulltext

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext

特别申明：文章原引内容及涉及字体图片等素材版权归原作者所有。本文章内容仅用于学习及学术交流，不做任何商业用途。

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of January 24, 2026, TenNor Therapeutics had built a pipeline of seven innovative programs, including two Core Products, namely, rifasutenizol (TNP-2198), a new molecular entity (“NME”) drug candidate used as part of a triple therapy in combination with amoxicillin and a proton pump inhibitor for the treatment of Helicobacter pylori (“H. pylori”) infection in China and U.S. as well as monotherapy for bacterial vaginosis and C. difficile infection in China; and rifaquizinone (TNP-2092 injection), a triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections, i.e. acute bacterial skin and skin structure infection (“ABSSSI”) and prosthetic joint infection (“PJI”), as well as left ventricular assist device infection (“LVADI”) and catheter-related bloodstream infection (“CRBSI”) in China and the U.S.

For more information, please visit: www.tennortherapeutics.com